Trade Ocuphire Pharma, Inc. - OCUP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 3.44 |
Open* | 3.45 |
1-Year Change* | 69.95% |
Day's Range* | 3.1 - 3.45 |
52 wk Range | 1.90-6.60 |
Average Volume (10 days) | 159.29K |
Average Volume (3 months) | 2.88M |
Market Cap | 83.82M |
P/E Ratio | 5.61 |
Shares Outstanding | 21.01M |
Revenue | 45.27M |
EPS | 0.71 |
Dividend (Yield %) | N/A |
Beta | 0.32 |
Next Earnings Date | Nov 2, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 29, 2023 | 3.31 | -0.15 | -4.34% | 3.46 | 3.51 | 3.05 |
Sep 28, 2023 | 3.44 | -0.37 | -9.71% | 3.81 | 3.81 | 3.38 |
Sep 27, 2023 | 3.73 | -0.26 | -6.52% | 3.99 | 4.10 | 3.58 |
Sep 26, 2023 | 3.99 | 0.16 | 4.18% | 3.83 | 4.38 | 3.83 |
Sep 25, 2023 | 3.88 | 0.02 | 0.52% | 3.86 | 3.89 | 3.80 |
Sep 22, 2023 | 3.83 | -0.04 | -1.03% | 3.87 | 3.94 | 3.80 |
Sep 21, 2023 | 3.86 | -0.03 | -0.77% | 3.89 | 3.92 | 3.82 |
Sep 20, 2023 | 3.94 | -0.01 | -0.25% | 3.95 | 3.96 | 3.91 |
Sep 19, 2023 | 3.99 | 0.05 | 1.27% | 3.94 | 4.01 | 3.90 |
Sep 18, 2023 | 3.94 | -0.04 | -1.01% | 3.98 | 4.02 | 3.91 |
Sep 15, 2023 | 3.97 | 0.06 | 1.53% | 3.91 | 4.05 | 3.91 |
Sep 14, 2023 | 3.99 | 0.06 | 1.53% | 3.93 | 4.02 | 3.79 |
Sep 13, 2023 | 3.87 | -0.16 | -3.97% | 4.03 | 4.07 | 3.85 |
Sep 12, 2023 | 4.05 | 0.07 | 1.76% | 3.98 | 4.07 | 3.97 |
Sep 11, 2023 | 4.00 | 0.01 | 0.25% | 3.99 | 4.01 | 3.89 |
Sep 8, 2023 | 3.97 | 0.03 | 0.76% | 3.94 | 4.07 | 3.93 |
Sep 7, 2023 | 3.95 | 0.19 | 5.05% | 3.76 | 3.97 | 3.76 |
Sep 6, 2023 | 3.79 | 0.00 | 0.00% | 3.79 | 3.84 | 3.74 |
Sep 5, 2023 | 3.82 | -0.11 | -2.80% | 3.93 | 3.96 | 3.78 |
Sep 1, 2023 | 3.89 | 0.01 | 0.26% | 3.88 | 3.96 | 3.86 |
Ocuphire Pharma, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, November 2, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Ocuphire Pharma Inc Earnings Release Q3 2023 Ocuphire Pharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 39.85 | 0.589 | 0 | 0 | 0 |
Revenue | 39.85 | 0.589 | 0 | 0 | |
Total Operating Expense | 21.624 | 23.29 | 16.292 | 11.215 | 20.5377 |
Selling/General/Admin. Expenses, Total | 7.269 | 8.121 | 2.818 | 5.72863 | 7.42862 |
Research & Development | 14.355 | 15.173 | 6.648 | 5.47678 | 13.1091 |
Unusual Expense (Income) | -0.004 | 6.826 | 0.00959 | ||
Operating Income | 18.226 | -22.701 | -16.292 | -11.215 | -20.5377 |
Interest Income (Expense), Net Non-Operating | -0.009 | -33.831 | -8.333 | 2.57957 | 5.80039 |
Net Income Before Taxes | 18.203 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Net Income After Taxes | 17.888 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Net Income Before Extra. Items | 17.888 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Net Income | 17.888 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Income Available to Common Excl. Extra. Items | 17.888 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Income Available to Common Incl. Extra. Items | 17.888 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Diluted Net Income | 17.888 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Diluted Weighted Average Shares | 20.5972 | 14.8527 | 4.66111 | 0.99004 | 0.68574 |
Diluted EPS Excluding Extraordinary Items | 0.86847 | -3.817 | -5.282 | -8.7223 | -20.9534 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | 0.86847 | -3.81727 | -3.81755 | -8.71261 | -20.9534 |
Other, Net | -0.014 | -0.161 | 0.005 | 0 | 0.36875 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 3.674 | 1.749 | 39.85 | 0 | 0 |
Total Operating Expense | 9.063 | 7.88 | 5.64 | 4.538 | 4.938 |
Selling/General/Admin. Expenses, Total | 4.34 | 2.285 | 2.054 | 1.703 | 1.776 |
Research & Development | 4.723 | 5.595 | 3.586 | 2.835 | 3.162 |
Unusual Expense (Income) | |||||
Operating Income | -5.389 | -6.131 | 34.21 | -4.538 | -4.938 |
Interest Income (Expense), Net Non-Operating | 0 | 0 | 0 | 0 | -0.004 |
Other, Net | 0.428 | 0.34 | 0.046 | 0.007 | 0.015 |
Net Income Before Taxes | -4.961 | -5.791 | 34.256 | -4.531 | -4.927 |
Net Income After Taxes | -4.961 | -5.791 | 33.941 | -4.531 | -4.927 |
Net Income Before Extra. Items | -4.961 | -5.791 | 33.941 | -4.531 | -4.927 |
Net Income | -4.961 | -5.791 | 33.941 | -4.531 | -4.927 |
Income Available to Common Excl. Extra. Items | -4.961 | -5.791 | 33.941 | -4.531 | -4.927 |
Income Available to Common Incl. Extra. Items | -4.961 | -5.791 | 33.941 | -4.531 | -4.927 |
Diluted Net Income | -4.961 | -5.791 | 33.941 | -4.531 | -4.927 |
Diluted Weighted Average Shares | 20.9598 | 20.9396 | 23.4819 | 20.4982 | 19.5026 |
Diluted EPS Excluding Extraordinary Items | -0.23669 | -0.27656 | 1.44541 | -0.22104 | -0.25263 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.23669 | -0.27656 | 1.44541 | -0.22104 | -0.25263 |
Revenue | 3.674 | 1.749 | 39.85 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 48.986 | 26.067 | 17.668 | 12.664 | 15.8997 |
Cash and Short Term Investments | 42.683 | 24.753 | 16.399 | 12.2168 | 14.7258 |
Cash & Equivalents | 42.634 | 24.534 | 16.399 | 9.21955 | 8.7443 |
Short Term Investments | 0.049 | 0.219 | 2.99722 | 5.98152 | |
Prepaid Expenses | 1.373 | 1.314 | 1.269 | 0.44721 | 0.55543 |
Other Current Assets, Total | 0.08 | 0 | 0.61842 | ||
Total Assets | 48.992 | 26.077 | 17.682 | 12.9688 | 16.0429 |
Property/Plant/Equipment, Total - Net | 0.006 | 0.01 | 0.014 | 0.27912 | 0.11247 |
Property/Plant/Equipment, Total - Gross | 0.025 | 0.025 | 0.025 | 0.55084 | 0.82159 |
Accumulated Depreciation, Total | -0.019 | -0.015 | -0.011 | -0.27172 | -0.70912 |
Long Term Investments | 0.02568 | 0.03079 | |||
Total Current Liabilities | 2.753 | 3.855 | 3.185 | 2.9055 | 3.15255 |
Accounts Payable | 1.069 | 1.584 | 1.214 | 0.48829 | 0.54752 |
Accrued Expenses | 1.369 | 1.733 | 1.971 | 0.91721 | 2.60503 |
Notes Payable/Short Term Debt | 0 | 0.538 | 0 | 0 | 0 |
Total Liabilities | 2.753 | 3.855 | 31.149 | 3.01082 | 5.48004 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 27.964 | 0.10532 | 2.32749 |
Total Equity | 46.239 | 22.222 | -13.467 | 9.95795 | 10.5629 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.002 | 0.002 | 0.001 | 0.0004 | 0.00375 |
Additional Paid-In Capital | 117.717 | 111.588 | 19.207 | 173.278 | 165.264 |
Retained Earnings (Accumulated Deficit) | -71.48 | -89.368 | -32.675 | -163.323 | -154.687 |
Other Equity, Total | 0.00208 | -0.01784 | |||
Total Liabilities & Shareholders’ Equity | 48.992 | 26.077 | 17.682 | 12.9688 | 16.0429 |
Total Common Shares Outstanding | 20.8613 | 18.8458 | 10.8825 | 1.00479 | 0.78179 |
Other Current Liabilities, Total | 0.315 | 0 | 1.5 | ||
Total Receivables, Net | 4.85 | ||||
Accounts Receivable - Trade, Net | 4.85 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 45.399 | 48.986 | 14.561 | 17.891 | 20.476 |
Cash and Short Term Investments | 39.01 | 42.683 | 13.956 | 17.151 | 19.381 |
Cash & Equivalents | 38.988 | 42.634 | 13.855 | 17.025 | 19.246 |
Prepaid Expenses | 1.01 | 1.373 | 0.544 | 0.709 | 1.095 |
Other Current Assets, Total | 0.078 | 0.08 | 0.061 | 0.031 | |
Total Assets | 45.404 | 48.992 | 14.568 | 17.899 | 20.485 |
Property/Plant/Equipment, Total - Net | 0.005 | 0.006 | 0.007 | 0.008 | 0.009 |
Property/Plant/Equipment, Total - Gross | 0.025 | 0.025 | 0.025 | 0.025 | 0.025 |
Accumulated Depreciation, Total | -0.02 | -0.019 | -0.018 | -0.017 | -0.016 |
Total Current Liabilities | 4.154 | 2.753 | 2.691 | 3.304 | 3.213 |
Accounts Payable | 2.221 | 1.069 | 1.468 | 1.886 | 1.579 |
Accrued Expenses | 1.618 | 1.369 | 1.223 | 1.418 | 1.419 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0.215 |
Total Liabilities | 4.154 | 2.753 | 2.691 | 3.304 | 3.213 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 0 | 0 | 0 |
Total Equity | 41.25 | 46.239 | 11.877 | 14.595 | 17.272 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 118.519 | 117.717 | 117.296 | 115.483 | 113.233 |
Retained Earnings (Accumulated Deficit) | -77.271 | -71.48 | -105.421 | -100.89 | -95.963 |
Total Liabilities & Shareholders’ Equity | 45.404 | 48.992 | 14.568 | 17.899 | 20.485 |
Total Common Shares Outstanding | 20.9478 | 20.8613 | 20.8015 | 20.0996 | 19.2136 |
Total Receivables, Net | 5.301 | 4.85 | |||
Accounts Receivable - Trade, Net | 5.301 | 4.85 | |||
Short Term Investments | 0.022 | 0.049 | 0.101 | 0.126 | 0.135 |
Other Current Liabilities, Total | 0.315 | 0.315 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 17.888 | -56.693 | -24.62 | -8.63543 | -14.3685 |
Cash From Operating Activities | 14.314 | -19.37 | -6.797 | -10.2771 | -18.8386 |
Cash From Operating Activities | 0.004 | 0.004 | 0.008 | 0.04099 | 0.04821 |
Non-Cash Items | 1.977 | 37.138 | 16.669 | -1.90774 | -4.66764 |
Changes in Working Capital | -5.555 | 0.181 | 1.146 | 0.22505 | 0.14932 |
Cash From Investing Activities | 0 | -0.1 | 0.539 | 3.09855 | 11.911 |
Capital Expenditures | 0 | -0.01938 | -0.03922 | ||
Other Investing Cash Flow Items, Total | 0 | -0.1 | 0.539 | 3.11793 | 11.9502 |
Cash From Financing Activities | 3.786 | 27.605 | 21.12 | 7.65383 | 6.77279 |
Issuance (Retirement) of Stock, Net | 4.455 | 28.578 | -0.448 | 7.65383 | 6.87279 |
Net Change in Cash | 18.1 | 8.135 | 14.862 | 0.47525 | -0.15485 |
Financing Cash Flow Items | -0.131 | -1.619 | 19.371 | 0 | -0.1 |
Cash Taxes Paid | 0 | 0 | 0 | ||
Cash Interest Paid | 0.009 | 0.002 | 0 | ||
Issuance (Retirement) of Debt, Net | -0.538 | 0.646 | 2.197 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -5.791 | 17.888 | -16.053 | -11.522 | -6.595 |
Cash From Operating Activities | -3.646 | 14.314 | -14.477 | -9.979 | -6.17 |
Cash From Operating Activities | 0.001 | 0.004 | 0.003 | 0.002 | 0.001 |
Non-Cash Items | 0.831 | 1.977 | 1.501 | 0.983 | 0.529 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0 | 0.009 | 0.009 | 0.009 | 0.005 |
Changes in Working Capital | 1.313 | -5.555 | 0.072 | 0.558 | -0.105 |
Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 |
Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | 0 |
Cash From Financing Activities | 0 | 3.786 | 3.798 | 2.47 | 0.882 |
Issuance (Retirement) of Stock, Net | 0 | 4.455 | 4.455 | 3.093 | 1.235 |
Issuance (Retirement) of Debt, Net | 0 | -0.538 | -0.538 | -0.538 | -0.323 |
Net Change in Cash | -3.646 | 18.1 | -10.679 | -7.509 | -5.288 |
Financing Cash Flow Items | 0 | -0.131 | -0.119 | -0.085 | -0.03 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ocuphire Pharma, Inc. Company profile
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.Industry: | Pharmaceuticals (NEC) |
37000 Grand River Ave.
Suite 120
FARMINGTON HILLS
MICHIGAN 48335
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com